These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 3162437)
21. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer. de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983 [TBL] [Abstract][Full Text] [Related]
22. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Crippa F; Buraggi GL; Di Re E; Gasparini M; Seregni E; Canevari S; Gadina M; Presti M; Marini A; Seccamani E Eur J Cancer; 1991; 27(6):724-9. PubMed ID: 1829912 [TBL] [Abstract][Full Text] [Related]
23. [Basic study for immunoscintigraphy of ovarian cancer using 99mTc labeled F(ab')2 fragments of monoclonal antibody]. Sugiyama S Kaku Igaku; 1994 Apr; 31(4):327-36. PubMed ID: 8196229 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Kraeber-Bodéré F; Mishra A; Thédrez P; Faivre-Chauvet A; Bardiès M; Imai S; Le Boterff J; Chatal JF Eur J Nucl Med; 1996 May; 23(5):560-7. PubMed ID: 8698062 [TBL] [Abstract][Full Text] [Related]
25. Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer. Ledermann JA; Marston NJ; Stahel RA; Waibel R; Buscombe JR; Ell PJ Br J Cancer; 1993 Jul; 68(1):119-21. PubMed ID: 8391302 [TBL] [Abstract][Full Text] [Related]
26. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma. Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic effect of a radiolabeled monoclonal antibody on human ovarian cancer xenograft in nude mice. Manetta A; Satyaswaroop PG; Hamilton T; Ozols R; Mortel R Gynecol Oncol; 1989 Mar; 32(3):368-70. PubMed ID: 2920960 [TBL] [Abstract][Full Text] [Related]
29. Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments. Barzen G; Mayr AC; Langer M; Becker R; Cordes M; Zwicker C; Koppenhagen K; Felix R Eur J Nucl Med; 1989; 15(1):42-8. PubMed ID: 2917583 [TBL] [Abstract][Full Text] [Related]
30. The use of radiolabelled monoclonal antibodies to human milk fat globule membrane antigens in antibody-guided tumour imaging, and administration of therapeutic dose of labelled antibody in wide-spread ovarian carcinoma. A preliminary report. Ashorn R; Ashorn P; Punnonen R; Pöyhönen L; Turjanmaa V; Koskinen M; Helle M; Uusitalo A; Pystynen P; Krohn K Ann Chir Gynaecol Suppl; 1985; 197():5-10. PubMed ID: 3863532 [TBL] [Abstract][Full Text] [Related]
31. Radionuclide imaging of ovarian tumours with a radiolabelled (123I) monoclonal antibody (NDOG2). Jackson PC; Pitcher EM; Davies JO; Davies ER; Sadowski CS; Staddon GE; Stirrat GM; Sunderland CA Eur J Nucl Med; 1985; 11(1):22-8. PubMed ID: 4043110 [TBL] [Abstract][Full Text] [Related]
32. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. van Zanten-Przybysz I; Molthoff CF; Roos JC; Verheijen RH; van Hof A; Buist MR; Prinssen HM; den Hollander W; Kenemans P Int J Cancer; 2001 Apr; 92(1):106-14. PubMed ID: 11279613 [TBL] [Abstract][Full Text] [Related]
34. Targetted localisation and imaging of a murine lymphoma using 131I-labelled monoclonal antibody. Subbiah K; Rayala SK; Ananthanarayanan M; Thangarajan R Indian J Exp Biol; 2001 Oct; 39(10):993-7. PubMed ID: 11883523 [TBL] [Abstract][Full Text] [Related]
35. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients. Buist MR; Kenemans P; den Hollander W; Vermorken JB; Molthoff CJ; Burger CW; Helmerhorst TJ; Baak JP; Roos JC Cancer Res; 1993 Nov; 53(22):5413-8. PubMed ID: 8221680 [TBL] [Abstract][Full Text] [Related]
36. Monitoring cancer antigen 125 in serum of ovarian cancer patients after administration of 131I-labeled F(ab')2 fragments of OC125 antibody. Reinsberg J; Schultes B; Wagner U; Krebs D Clin Chem; 1993 May; 39(5):891-6. PubMed ID: 8485883 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961 [TBL] [Abstract][Full Text] [Related]
38. [Biodistribution, pharmacokinetics and imaging of 131I-labeled HMD4 human McAb in human ovarian carcinoma xenograft in nude mice]. Cui H Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):80-3, 123. PubMed ID: 2364795 [TBL] [Abstract][Full Text] [Related]
39. Immunoscintigraphy with 131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients. Pectasides D; Pateniotis K; Tzimis L; Trapalli X; Natsis P; Arapantoni P; Taylor-Papadimitriou J; Epenetos A; Koutsiouba P; Athanassiou A Int J Cancer Suppl; 1988; 3():83-8. PubMed ID: 3209305 [TBL] [Abstract][Full Text] [Related]
40. OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment. Maughan TS; Haylock B; Hayward M; Facey P; Evans WD; Shelley MD; Fish RG; Adams M Clin Oncol (R Coll Radiol); 1990 Jul; 2(4):199-205. PubMed ID: 2261415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]